---
document_datetime: 2024-03-14 08:40:25
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/sustiva-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: sustiva-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 3.3581944
conversion_datetime: 2025-12-22 13:46:06.932074
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

<!-- image -->

For procedures finalised after 1 March 2004 please refer to module 8B . · On 4 June 1999, the Marketing Authorisation Holder submitted to the EMEA an application for a Type I variation related to the extension of the shelf life. The EMEA approved this variation on 8 July 1999 which required amendments to Annexes of the Commission Decision. · On 16 July 1999, the Marketing Authorisation Holder submitted to the EMEA an application for  a  Type  II  variation  related  to  the  update  of  the  Summary  of  Product  Characteristics  and Package Leaflet with new data based on 1) reports of genotyping of virus from clinical isolates, 2)  updated  clinical  study  reports  and  3)  revised  safety  information  resulting  from  increased patient  exposure.  The  CPMP,  during  its  September  plenary  meeting,  considered  the  changes acceptable, and adopted on 23 September 1999 a favourable opinion on the Type II variation. The corresponding Commission Decision was issued on 31 January 2000. · On 28 July 1999, the Marketing Authorisation Holder submitted to the EMEA an application for  a  Type  I  variation  related  to  a  change  in  the  qualitative  composition  of  the  immediate packaging material (bottles). The EMEA approved on 11 August 1999 this variation which did not require any amendments to Annexes of the Commission Decision. · On  9  November  1999,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an application  for  a  Type  II  variation  related  to  the  update  of  the  Summary  of  Product Characteristics  to  reflect  results  from  the  48  weeks  paediatric  study.  The  CPMP,  during  its January plenary meeting, considered the changes acceptable, and adopted on 19 January 2000 a favourable  opinion  on  the  Type  II  variation.  The  corresponding  Commission  Decision  was issued 24 May 2000. · On  28  January  2000,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an application  for  a  Type  I  variation  related  to  an  extension  of  the  re-test  period  of  the  active substance.  The  EMEA  approved  on  2  March  2000  this  variation,  which  did  not  require  any amendments to Annexes of the Commission Decision. · On 30 March 2000, the Marketing Authorisation Holder submitted to the EMEA an application for  a  Type  II  variation  related  to  the  update  of  the  Summary  of  Product  Characteristics  and Package  Leaflet  in  particular  to  reflect  new  data  on  food  interaction  and  safety  information. The CPMP, during its June plenary meeting, considered the changes acceptable, and adopted on 29 June 2000 a favourable opinion on the Type II variation. The corresponding Commission Decision was issued 13 October 2000. · Pursuant  to  CPMP  discussion  on  the  potential  of  St  John's  wort  ( Hypericum  perforatum )  to interact  with  protease  inhibitors  (PIs)  and  non-nucleoside  reverse  transcriptase  inhibitors (NNRTIs), the MAHs for the respective PIs and NNRTIs submitted to the EMEA an application for  a  Type  II  variation  to  include  a  class  labelling  wording  in  the  Summary  of  Product Characteristics and Package leaflet. On 29 June 2000, the CPMP adopted an Opinion on this variation and the respective Commission Decision was issued on 13 October 2000. On 10 May 2000, the Marketing Authorisation Holder submitted to the EMEA an application for  a  Type  II  variation  related  to  the  introduction  of  an  alternative  route  of  synthesis  of  the active  substance.  The  CPMP,  during  its  July  plenary  meeting,  considered  the  changes acceptable, and adopted on 27 July 2000 a favourable opinion on the Type II variation, which did not require any amendments to the Commission decision. Medicinal product no longer authorised

•

- On  24  October  2000,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an application for a Type I variation related to a change of the batch size of the active substance. The  EMEA  approved  on  24  November  2000  this  variation,  which  did  not  require  any amendments to Annexes of the Commission Decision.
- On  30  November  2000,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an application  for  a  Type  II  variation  related  to  the  addition  of  an  alternate  manufacturer  of  the

<div style=\"page-break-after: always\"></div>

active  substance  and  to  the  redefinition  of  the  starting  material  for  the  synthetic  route  of  the active substance.

| Scope                                                                                                                                                                                                                                  | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amended on   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|-----------------------------------------|
| Change to demonstrate compliance with Commission Directive 1999/82/EC and the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products (CPMP/BWP/1230/98 rev.1) product | I/16                 | I                        | 28.03.01                            | 05.05.01                                |
| The MAH submitted to the EMEA on 4 May 2001, an Annex II application. The existing numbers in the Community Register of Medicinal Products for Sustiva, are: EU/1/99/110/001-005                                                       | X/17                 | X                        | 30.05.02                            | 22.08.02                                |
| The MAH submitted to the EMEA on 4 May 2001, an Annex II application. The existing numbers in the Community Register of Medicinal Products for Sustiva, are: EU/1/99/110/001-005                                                       | X/18                 | X                        | 30.05.02                            | 22.08.02                                |
| The MAH applied for an update of the Summary of Product Characteristics (SPC) section 4.4 (Special warnings and special precautions for use) and section 5.3 (Preclinical safety data).                                                | II/19                | II                       | 13.12.01                            | 12.04.02                                |
| Changes to comply with supplements to pharmacopoeias                                                                                                                                                                                   | I/20                 | I                        | 21.09.01                            | 23.10.01                                |
| Change in container shape                                                                                                                                                                                                              | I/21                 | I                        | 24.10.01                            | 07.01.02                                |
| Change in or addition of manufacturing site(s) for part or all of the manufacturing process and consequential change                                                                                                                   | I/22                 | I                        | 26.11.01                            | 06.03.02                                |
| Change in the name and/or address of the marketing authorisation holder                                                                                                                                                                | I/23                 | I                        | 31.10.01                            | 21.03.02                                |
| Change following modification(s) of the manufacturing authorisation(s).                                                                                                                                                                | I/24                 | I                        | 31.10.01                            | 21.03.02                                |

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application.

The  CPMP,  during  its  February  plenary  meeting,  considered  the  changes  acceptable,  and adopted on 1 March 2001 a favourable opinion on the Type II variation, which did not require any amendments to the Commission decision. · On  30  November  2000,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an application  for  a  Type  II  variation  related  to  the  update  of  the  Summary  of  Product Characteristics and Package Leaflet following the evaluation of the 2 nd Periodic Safety Update Report  and  the  availability  of  clinical  data  regarding  the  interaction  between  efavirenz  and rifabutin. The CPMP, during its February plenary meeting, considered the changes acceptable, and adopted on 1 March 2001 a favourable opinion on the Type II variation. The corresponding Commission Decision was issued 14 June 2001. · On  14  February  2001  The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an application for a type II variation related the update of the Summary of Product Characteristics to  reflect  results  from  indinavir/efavirenz  steady  state  pharmacokinetics  study.  The  procedure started on 2 March  2001.  Supplementary  information  was  supplied  by  the  Marketing Authorisation Holder on 4 May 2001. The CPMP, during its May plenary meeting, considered the changes acceptable, and adopted on 31 May June 2001 a favourable opinion on the Type II variation. The corresponding Commission Decision was issued 20 September 2001. · On 28 March 2000 The Marketing Authorisation Holder submitted to the EMEA an Annex II application Pursuant to Article 2(1) of Commission Regulation (EC) No 542/95 of 10 March 1995, as amended, and Annex  II point 3(iv) The procedure started on 14 April 2000, The CPMP, during its June plenary meeting, considered the changes acceptable, and adopted on 27 June 2001 a favourable opinion on the Type II variation. The corresponding Commission Decision was issued 18 October 2001. Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: Medicinal product no longer authorised

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 61(3) of Council Directive 2001/83/EC.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Change following modification(s) of the manufacturing authorisation(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | I/25         | I   | 31.10.01   | 06.03.02            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|------------|---------------------|
| The MAH applied for an update of the SPC sections 4.3, 4.4, 4.5 and 4.8 and corresponding sections of the Package leaflet (PL). The application is based on newly completed interaction studies and on two adverse events reported in the 4 th efavirenz PSUR. In addition, a class wording on St-John's Wort is added, as agreed with CPMP.                                                                                                                                                                                                                                                                                         | II/27        | II  | 27.06.02   | 30.09.02 authorised |
| Bristol-Myers Squibb Pharma (UK) Limited submitted to the EMEA on 21 January 2002 an application for the transfer of the Marketing Authorisation to Bristol-Myers Squibb Pharma EEIG                                                                                                                                                                                                                                                                                                                                                                                                                                                 | T/28         | T   | 28.02.02   | 02.04.02            |
| Update of the SPC for the oral solution in order to include information on the final results of study DMP266-111, 'A Phase I, Open-label, Single-dose, Randomized; Two-period Crossover Study in Healthy Volunteers to Determine the Effect of Food on the                                                                                                                                                                                                                                                                                                                                                                           | II/29        | II  | 30.05.02   | 30.08.02            |
| Change following modification(s) of the manufacturing authorisation(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | I/30         | I   | 09.04.02   | 07.05.02            |
| Changes to the PL local representatives address for France, Finland and Ireland. The phone numbers for the local representatives in Greece and Germany are modified. Local representatives for Belgium, Luxembourg, Ireland and UK are listed individually in accordance with the latest QRD template.                                                                                                                                                                                                                                                                                                                               | N/31         | N   | 20.06.02   | 20.06.02            |
| Changes of the local representative name in Italy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | N/32         | N   | 14.06.02   | 10.07.02            |
| Changes of the local representative names in Italy and Spain. The phone number for the local representative in Ireland is modified.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | N/33         | N   | 18.11.02   | 04.12.02            |
| To amend sections 4.4 and 4.8 of the SPC as requested by the CPMP on July 2002, following the assessment of PSUR 5, in order to adequately reflect the safety concerns with regard to suicide. In particular, the Marketing Authorisation Holder (MAH) was requested to delete 'occasional' in sections 4.4 and 4.8 and 'a causal relationship to the use of efavirenz cannot be determined from these reports' in sections 4.8. Moreover, the MAHtook this opportunity to update the SPC and the PL of the 300mg and the 600mg film-coated tablet presentations, following variation II/27 for Sustiva, adopted at the June 2002 no | II/34 longer | II  | 20.02.03   | 19.05.03            |
| The MAH applied for an update of the SPC to include the class labelling on Lipodystrophy in sections 4.4 and 4.8. Relevant changes are equally proposed for the Package Leaflet.                                                                                                                                                                                                                                                                                                                                                                                                                                                     | II/35        | II  | 19.03.03   | 09.07.03            |
| Extension of shelf-life as foreseen at time of authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | I/36         | I   | 08.05.03   | 25.06.03            |
| Minor changes in manufacture of the medicinal productChange in or addition of manufacturing site(s) for part or all of the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | I/37         | I   | 07.07.03   | 22.07.03            |
| Update of section 4.4 (Special warnings and special precautions of use) and 5.2 (Pharmacokinetic properties) of the SPC to implement the class labelling on liver impairment adopted by the CPMP for all anti-retroviral medicinal products on 25 April 2003. Furthermore, the MAH has taken this opportunity to update section 4.4 of the SPC, by reordering the wording on lactose (for the 300 and 600 mg tablet formulations only), on cholesterol and on lipodystrophy. In addition, the MAH has proposed to update the PL in line with the proposed changes of the SPC and to include the wording on product                   | II/38        | II  | 20.11.03   | 05.02.04            |
| Addition or replacement of measuring device for oral liquid dosage forms and other dosage forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | I/39         | I   | 16.10.03   | 23.10.03            |
| Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | IA/42        | IA  | 17.11.03   | -                   |
| Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | IA/44        | IA  | 27.01.04   | -                   |
| Deletion of manufacturing site Replacement/add. of manufacturing site: Primary packaging site -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | IA/45        | IA  | 30.01.04   | -                   |